Results 21 to 30 of about 2,675,396 (301)
Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease [PDF]
The Korean Journal of Internal Medicine, 2021 Background/Aims Combination therapy with immunomodulators (IMMs) was proposed as a strategy to prevent the development of loss of response (LOR) to anti-tumor necrosis factor (TNF) for patients with inflammatory bowel disease (IBD).
Seung Wook Hong +8 more
doaj +1 more source
The Safety of Anti-TNF Agents in the Elderly [PDF]
International Journal of Immunopathology and Pharmacology, 2009 Rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis are commonly thought of as inflammatory diseases that affect younger individuals. Although the initial presentation of these diseases is common in a patient's twenties or thirties, they usually persist for the duration of the patient's life.
A. Migliore +15 more
openaire +6 more sources
Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic [PDF]
, 2009 Depression is common in RA and may be influenced by both disease activity and severity. The aims of this study were to investigate the prevalence of depression in RA patients starting anti-TNF therapy, to investigate how mood alters after exposure to ...
core +1 more source
Successful Treatment of Paradoxical Psoriasis with IL 17 Inhibition: Case Reports
Boğaziçi Tıp Dergisi, 2020 Paradoxical psoriasis (PPs) is new-onset psoriatic skin lesions or worsening of the existing psoriatic skin lesions during anti-TNF therapy. PPs occurs in 2-5% of patients using anti TNF drugs (1).
Gamze Gül Güleç +4 more
doaj +1 more source
Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type [PDF]
Journal of Crohn's and Colitis, 2018 Pregnancy guidelines for women with inflammatory bowel disease [IBD] provide recommendations regarding anti-TNF cessation during pregnancy, in order to limit foetal exposure. Although infliximab [IFX] leads to higher anti-TNF concentrations in cord blood than adalimumab [ADA], the recommendations are similar.
Kanis, Shannon +4 more
openaire +3 more sources
Drug Delivery, 2019 Biologic drugs (e.g. anti-tumor necrosis factors) are effective treatments for multiple chronic inflammatory diseases including rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis.
Bart J. F. van den Bemt +5 more
doaj +1 more source
Anti‐TNF agents for rheumatoid arthritis [PDF]
British Journal of Clinical Pharmacology, 2001 Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease with a prevalence of approximately 1% and an annual incidence of 0.04%. Up to 50% of patients with RA are unable to work 10 years after diagnosis. The disease is associated with significant morbidity and mortality with associated medical costs to the UK of between £240 m and £600 m
Thomas, SHL +3 more
openaire +4 more sources
, 2022 Tumour Necrosis Factor-alpha (TNF-α) is one of the main drivers of inflammatory bowel disease (IBD). Regulating the actions of this pro-inflammatory cytokine through selective antagonism using an anti-TNF-α monoclonal antibody (mAb) provides effective
Owen Rees Griffiths (13040982)
core +1 more source
Mucosal Healing with Anti-TNF Antibodies [PDF]
Digestion, 2012 Nowadays, mucosal healing is regarded as a major end point in clinical trials and is increasingly used in clinical practice for the management of patients with inflammatory bowel disease. The definition of mucosal healing varies across studies and validated endoscopic scoring indices are still lacking.
Chevaux, Jean-Baptiste +5 more
openaire +2 more sources
Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
Biologics: Targets & Therapy, 2022 Valeria Dipasquale, Ugo Cucinotta, Claudio Romano Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood “G.
Dipasquale V, Cucinotta U, Romano C
doaj